The FDA on December 18, 2019 granted accelerated approval to PADCEV® for adult patients with locally advanced or metastatic urothelial cancer who have previously received a Programmed Death receptor-1 (PD-1) or Programmed Death-Ligand 1 (PD-L1) inhibitor, and a Platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. PADCEV® is a product of Astellas Pharma US, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
